Slide 1: Q4 and FY 2025 results
Q4 and FY 2025 results Continuously delivering solid profitable growth February 4, 2026
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements contained in this presentation may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1
Slide 3: Q4 and FY 2025: Solid results with adjusted EPS exceeding outlook
Q4 and FY 2025: Solid results with adjusted EPS exceeding outlook Growth 2025 FY: $2.090 bn Q4 growth ahead of outlook and FY 2025 growth at high end of outlook ($2.069 bn CER) • Q4: +1% CER growth above outlook of ~+0% CER Net sales • FY: +5% CER growth at high end of outlook of ~+4-5% CER Q4: $540
Slide 4: Q4 2025: Sales performance and key developments
Q4 2025: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) +1% Sample • +5% CER growth driven by automated consumables CER(1) technologies • Parse acquisition adds highly scalable single-cell kits 521 540 • +5% CER growth on gains in U.S a
Slide 5: Q4 2025: Portfolio developments
Q4 2025: Portfolio developments Sample technologies: QIAstat-Dx: Parse: Breaking single-cell limits Expanding syndromic testing access Expanding Sample technologies into scalable Submission of blood culture identification single-cell workflows (BCID) panels • Acquisition of Parse, adding single-cell
Slide 6: Q4 2025: Advancing automation of QuantiFERON test
Q4 2025: Advancing automation of QuantiFERON test Why does QuantiFERON win? UNIVERSAL AUTOMATION WORKFLOW customizable to labs of all sizes with fast time to result WELL ESTABLISHED AND DIFFERENTIATED QuantiFERON testing infrastructure Launch of next-generation LIAISON NEW QuantiFERON-TB Gold Plus I
Slide 7: FY 2025: Sales performance and key developments
FY 2025: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) • QIAsymphony Connect launched, QIAsprint Connect and +5% Sample QIAmini on track for launch in 2026 CER(1) technologies • Parse expands reach into clinical and translational workf
Slide 8: 2025: Adjusted EPS growth supported by operating profitability
2025: Adjusted EPS growth supported by operating profitability Adj. operating income margin Adj. diluted EPS ahead of Q4 and FY 2025 outlook ~+2 ppt 29.5% ~-1 ppt ~+1.6 ppt Q4 2025: $0.62 28.7% ~-0.8 ppt Adj. EPS(1) ~-0.5 ppt $0.62 CER vs. ~$0.60 CER outlook ~-0.4 ppt ~-0.1 ppt FY 2025: $2.38 Adj. E
Slide 9: Q4 and FY 2025: Continued solid operating cash flow generation
Q4 and FY 2025: Continued solid operating cash flow generation Cash flow(1) Debt maturity overview(3) 770 (in $ millions) 20 In $ millions Q4 2025 Operating cash flow 188 Purchases of PP&E(2) -71 500 Free cash flow 117 750 151 165 In $ millions FY 2025 82 125 Operating cash flow 654 26 Purchases of
Slide 10: 2026: Preparing for future growth across pillars
2026: Preparing for future growth across pillars Sample tech QuantiFERON QIAcuity QIAstat-Dx QDI Leveraging automation in Advancing workflow and Driving growth and preparing Broadening syndromic Capitalizing on top market high-value areas customer retention new generation testing panels position wit
Slide 11: 2026: Leveraging a solid portfolio to drive growth
2026: Leveraging a solid portfolio to drive growth Sample tech QuantiFERON QIAcuity QIAstat-Dx QDI Growth pillars total sales (CER) $1.49 bn 2025 target achieved $653 mn $501 mn $87 mn $136 mn $112 mn CER sales 8% CER growth 2025 $1.49 bn ~$650 mn ~$500 mn ~$105 mn ~$130 mn ~$105 mn CER targets ~$1.
Slide 12: Adj. operating income margin expansion
Adj. operating income margin expansion ~+2 ppt 29.5% ~-1 ppt ~+1.6 ppt ~29.5% 28.7% ~-0.8 ppt ~-0.5 ppt ~-0.4 ppt ~-0.1 ppt FY 2024 Tariff Currency Efficiency FY 2025 Parse Currency Tariff Efficiency FY 2026 headwinds movements program acquisition movements(1) headwinds program (incremental) Continu
Slide 13: FY 2026 growth trajectory driven by accelerators in H2
FY 2026 growth trajectory driven by accelerators in H2 7% ~+0.5 ppt ~+7-8% ~+0.5 ppt 6% ~+2 ppt 5% 5,0 ~+2 ppt ~+2-3% 1% Q1 2025 Q2 2025 Q3 2025 Q4 2025 H1 2026 End of New Sample QuantiFERON Better U.S. H2 2026 CER NeuMoDx, tech systems, Life Science CER growth Dialunox new product environment growt
Slide 14: 2026 outlook: Positioned for growth
2026 outlook: Positioned for growth Drive solid sales growth through pillars Our 2028 targets Launch new platforms and expand menu to drive recurring revenues ~7% Net sales CER CAGR Leverage portfolio in high-value areas (2024-28) Increase focus on applications offering dynamic growth ≥31% Deliver v
Slide 15: Transition in QIAGEN Supervisory Board
Transition in QIAGEN Supervisory Board Mark Stevenson QIAGEN Supervisory Board members – Appointed to Supervisory Board in 2026 Extensive industry and international experience • New independent member of the Supervisory Board in January 2026 • Brings extensive operational leadership and Stephen H. R
Slide 16: Q1 and FY 2026: Outlook and assumptions
Q1 and FY 2026: Outlook and assumptions (As of February 4, 2026) Q1 2026 outlook FY 2026 outlook Net sales ≥+1% CER ≥+5% CER Anticipated currency impact(1) Positive impact of ~+2-3 ppt Positive impact of ~+1 ppt Adjusted diluted EPS(2) ≥$0.54 CER ≥$2.50 CER Anticipated currency impact(1) Neutral Neu
Slide 17: Appendix
QIAGEN Appendix
Slide 18: Q4 2025: Consolidated Statements of Income (unaudited)
Q4 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended December 31, 2025 December 31, 2024 Net sales 540,420 521,202 Cost of sales: Cost of sales 200,240 174,401 Acquisition-related intangible amortization 14,911 13,511 Total
Slide 19: FY 2025: Consolidated Statements of Income (unaudited)
FY 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Twelve months ended Twelve months ended December 31, 2025 December 31, 2024 Net sales 2,089,999 1,978,214 Cost of sales: Cost of sales 735,268 952,323 Acquisition-related intangible amortization 55,236 58,541
Slide 20: 2025: Quarterly sales by product group
2025: Quarterly sales by product group Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 150 -3% -1% 166 2% 0% 170 5% 3% 175 8% 5% 661 3% 2% Diagnostic s
Slide 21: 2025: Quarterly sales by product type and region
2025: Quarterly sales by product type and region Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 435 6% 8% 476 8% 6% 481 7% 6% 484 5%
Slide 22: Q4 and FY 2025: Reconciliation to adjusted results (unaudited)
Q4 and FY 2025: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* Fourth quarter 2025 Reported results 540.4 325.3 99.5 109.2 (1.4) 1 % 107.8 0.49 Adjustments Business integrat
Slide 23: Q4 and FY 2025: Footnotes for reconciliation to adjusted results
Q4 and FY 2025: Footnotes for reconciliation to adjusted results (unaudited) a. Results include costs for acquisition projects, including the acquisition of GNX Data Systems Ltd. (doing business as Genoox) completed in May 2025 and Parse Biosciences completed in December 2025. It also includes costs
Slide 24: 2025: Quarterly income statement summary
2025: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Net sales 483.5 533.5 532.6 540.4 2,090.0 Net sales (CER) 491.2 525.8 524.8 527.4 2,069.0 Gross profit 308.7 334.3 331.3 325.3 1299.5 Gross profit margin 63
Slide 25: Consolidated Balance Sheets (unaudited)
Consolidated Balance Sheets (unaudited) December 31, December 31, December 31, December 31, (In $ thousands, except par value) 2025 2024 (In $ thousands, except par value) 2025 2024 (revised) (revised) Assets Liabilities and Equity Cash and cash equivalents 839,005 663,555 Current portion of long-te
Slide 26: Consolidated Statements of Cash Flows (unaudited)
Consolidated Statements of Cash Flows (unaudited) Twelve months ended December 31, December 31, Twelve months ended December 31, December 31, (In $ thousands) 2025 2024 (In $ thousands) 2025 2024 Cash flows from operating activities: Cash flows from financing activities: Net income 424,880 83,591 Pr
Slide 27: Q4 and FY 2025: Currency impact
Q4 and FY 2025: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q4 2025 U.S. dollar 293.3 293.4 56% 0.1 Euro 114.1 104.6 20% -9.5 British pound 18.9 18.3 3% -0.6 Japanese yen 11.1 11.2 2% 0.1 Other currencies 103.0 99.9
Slide 28: Employees as of December 31, 2025
Employees as of December 31, 2025 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q4 2025 Q3 2025 Change Production 294 1,106 142 1,542 1,530 1% R&D 170 750 55 975 992 -2% Sales 584 833 702 2,119 2,126 0% Marketing 76 174 71 321 319 1% Administration 86 455 156 697 693
Slide 29: Your contacts
Your contacts Daniel Wendorff Calendar Vice President E-mail: Head of Investor Relations Q1 2026 results May 2026 ir@qiagen.com Phone: +49 2103 29 11322 Internet: Annual General Meeting June 2026 E-mail: daniel.wendorff@qiagen.com corporate.QIAGEN.com Q2 2026 results August 2026 Dr. Domenica Martora